Keep reading to learn about the common, mild, and serious side effects that Dupixent can cause. For a detailed overview of this drug, check out this in-depth Dupixent article. Some people may ...

Dupixent (dupilumab) is a prescription drug that’s used to treat certain inflammatory conditions, such as atopic dermatitis (a type of eczema). Dupixent comes in a prefilled syringe or prefilled ...

Sanofi SNY and partner Regeneron REGN announced that the FDA has accepted their resubmitted supplemental biologics license ...

Resubmission includes new pivotal data which confirm Dupixent significantly reduced itch and hive activityMore than 300,000 people in the U.S.

The FDA has accepted for review the resubmitted sBLA for dupilumab for the treatment of chronic spontaneous urticaria.

Swiss skincare company Galderma is banking on a drug for eczema treatment to revive sales growth at its pharmaceutical ...

Regeneron Pharmaceuticals Inc. claims that a partner has broken a collaboration deal by refusing to reveal side deals for marketing ...

Sanofi plans to phase in its own rebate model for 25 drugs — including anti-inflammatory injectable Dupixent, one of the top ...

Sanofi and Regeneron’s Dupixent (dupilumab) has been approved by the European Commission (EC) to treat eosinophilic oesophagitis (EoE) in young patients. The drug has been specifically authorised for ...

That $51.5 million is also easily the highest single total spent on ads for a drug during one month this year. In second place is fierce rival Dupixent, the immunology megablockbuster from Sanofi ...